Novo Nordisk and Valo Health, an AI-focused biotech, have expanded their existing collaboration to discover and develop new treatments targeting cardiometabolic diseases. The companies entered the agreement in 2023 to jointly advance as many as 11 drug programs, mainly targeting cardiovascular diseases. Under the terms, Valo was initially entitled to receive as much as $2.7 billion in milestone payments as well as R&D funding and royalty payments from Novo Nordisk. The expanded collabo...